Evidence is presented showing that DFX treatment reduces TNF-alpha bioavailability ( P<0 . 05 ) by inhibiting its steady state ( P<0 . 05 ) and by enhancing its inactivation through binding to soluble TNF-alpha receptor type II ( P<0 . 05 ) .
evidence is presented showing that dfx treatment reduces tnf-alpha bioavailability ( p<0 . 05 ) by inhibiting its steady state ( p<0 . 05 ) and by enhancing its inactivation through binding to soluble tnf-alpha receptor type ii ( p<0 . 05 ) .
O O O O O B-other_organic_compound O O B-protein_molecule O O O O O O O O O O O O O O O O O O O O O O O O O B-protein_molecule O O O O O O O O O